While the definitive role of GLP-1 RAs in oncological treatment is still under active investigation, an increasing body of recent preclinical evidence suggests that these agents may possess significant anticancer properties, potentially expanding their therapeutic applications beyond their established use in metabolic disorders such as T2DM. This evidence concerns the gene GLP1R and metabolic disease.